Tenaya Therapeutics
Price & Volume
Stats
See more52W Range | $0.39-$2.35 |
Market Cap | $196.9M |
Shares Short | 27M |
Financials
See moreRevenue (12 Mos) | $225,000 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $225,000 |
Diluted EPS | -$0.44 |
News
See moreYahoo Finance • 2 days ago
Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC
Yahoo Finance • 18 days ago
US High Growth Tech Stocks To Watch Now
Yahoo Finance • 19 days ago
Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026
Yahoo Finance • 2 months ago
Alnylam Tenaya Cardiovascular RNAi Pact And What It Means For Valuation
About
CEO | Mr. Faraz Ali M.B.A. |
Address | 171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 70 |